Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLB | Q8NCG7 | 4/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120295 | 0.88 | TLR9 (0.45) | DAGLBTLR9TLR7METTL3HCRTR1 | |
| SCHEMBL27808115 | 0.81 | KDM4E (0.54) | HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL4163082 | 0.81 | KDM4E (0.54) | HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL3470831 | 0.80 | ALDH1A1 (0.39) | DAGLBHCRTR1KDM4EALDH1A1POLB | |
| SCHEMBL2616561 | 0.79 | HCRTR1 (0.61) | HCRTR1 | |
| SCHEMBL8138340 | 0.78 | DAGLA (0.40) | DAGLBTLR9TLR7METTL3HCRTR1 | |
| SCHEMBL3251052 | 0.77 | PDE8B (0.38) | DAGLBKDM4EALDH1A1POLBHPGD | |
| SCHEMBL8160273 | 0.75 | KDM4E (0.51) | METTL3HCRTR1TP53KDM4EALDH1A1 | |
| SCHEMBL2120937 | 0.74 | METTL3 (0.44) | TLR9TLR7METTL3KDM4EALDH1A1 | |
| SCHEMBL3676086 | 0.74 | KDM4E (0.56) | KDM4EALDH1A1POLBHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | DAGLB 3924/4885TLR9 4690/4885TLR7 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.